Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2011-08-03 Regulatory Filings
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a press release from ALK announcing the successful outcome of two Phase III clinical studies for a new ragweed tablet. It details the efficacy endpoints, safety profile, partnership with Merck, and future plans for data presentation. This type of announcement, focusing on clinical trial results and strategic updates, is typically classified as a general regulatory announcement or news release, as it does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or specific corporate actions (like DIV, CAP, MANG). Given the options, 'Regulatory Filings' (RNS) serves as the best general category for significant, non-standard regulatory/clinical news releases that are not explicitly defined elsewhere. It is not an Earnings Release (ER), Interim Report (IR), or a specific legal/governance document. Since it is a news announcement about clinical progress, RNS is the most appropriate fallback.
2011-08-03 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a formal announcement titled "Company release No 12/2011" addressed to NASDAQ OMX Copenhagen A/S. It details the successful outcome of Phase III clinical studies for a new drug (Ragweed Allergy Immunotherapy Tablet). This type of announcement, focusing on clinical trial results and strategic updates, is typically classified as a general regulatory announcement or a specific corporate update. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it is a formal communication to the exchange, it fits best under the general Regulatory Filings category (RNS) or potentially a specific announcement type if one were more fitting. Given the content is a scientific/clinical update rather than a financial result or governance change, RNS serves as the most appropriate general regulatory filing category for non-standard disclosures.
2011-08-03 English
Regulatory Filings 2011
Regulatory Filings Classification · 100% confidence The document is a press release dated 2011-07-14 announcing a strategic agreement between ALK and AllerQuest regarding the development and commercial rights for a new diagnostic product (MDM) that complements an existing product (PRE-PEN®). It details financial considerations (up to USD 3.45 million) and future regulatory steps (FDA submission in 2012). This type of announcement, detailing a significant business transaction, partnership, or material development that is not a standard periodic financial report (like 10-K or IR), typically falls under general corporate news or regulatory filings. Since it is a specific announcement about a transaction/partnership rather than a change in management (MANG), dividend (DIV), or capital structure (CAP), and it is not a standard financial report, it best fits the 'Regulatory Filings' (RNS) category as a general corporate announcement, or potentially 'M&A Activity' (TAR) if the agreement were structured as an acquisition, which it is not. Given the options, RNS serves as the best general category for material, non-standard corporate news releases.
2011-07-14 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a press release dated July 14, 2011, announcing a strategic agreement between ALK and AllerQuest regarding the development and marketing of a new diagnostic product for penicillin allergy (MDM) and the extension of rights for PRE-PEN®. This type of announcement, detailing a significant business development, partnership, or transaction that is not a standard periodic financial report (like 10-K or IR), typically falls under general regulatory announcements or corporate actions. Since it is a specific business development announcement and not a standard financial filing, and it doesn't fit perfectly into categories like M&A (TAR) or Capital Change (CAP), it is best classified as a general Regulatory Filing (RNS) or potentially a general corporate update. Given the context of corporate filings, RNS serves as the appropriate catch-all for material, non-standard announcements released via news wires (GLOBE NEWSWIRE is mentioned). The length (4616 chars) suggests it is the full announcement, not just a brief notice of publication.
2011-07-14 Danish
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a press release dated June 30, 2011, announcing specific corporate and clinical development updates. Key events mentioned are: 1) Submission of a registration application (NDS) for Grass AIT in Canada, triggering a milestone payment. 2) Adjustment of the full-year EBITDA outlook upwards due to this payment. 3) Initiation of an additional clinical study for Grass AIT in North America. 4) Anticipation of Phase III results for Ragweed AIT in Q3 2011. This content details operational and financial progress, which aligns best with an Earnings Release (ER) or a general announcement that might accompany financial reporting, but since it focuses on specific financial guidance changes (EBITDA outlook adjustment) and key operational milestones, it fits the 'initial announcement of periodical financial results (key highlights only)' definition of an Earnings Release (ER). It is not a full report (10-K or IR), a transcript (CT), or a formal proxy/governance document.
2011-06-30 English
Earnings Release 2011
Earnings Release Classification · 92% confidence The document is a 'Selskabsmeddelelse' (Company Announcement) from ALK, dated June 30, 2011. It details specific operational and financial updates related to their partnership with Merck, including the submission of a registration application (NDS) in Canada, which triggers a milestone payment, leading to an upward revision of the 2011 EBITDA guidance. It also discusses ongoing clinical trials and expected results. This type of announcement, focusing on material, non-periodic business developments, financial guidance changes, and partnership progress, is best classified as an Earnings Release (ER) if it were quarterly results, but since it is a specific, material update outside of standard reporting cycles, and it is not a transcript (CT), a formal annual report (10-K), or a general regulatory filing (RNS), it fits best under the category of an initial announcement of key financial/operational highlights. Given the focus on financial guidance revision (EBITDA up-revision) and key operational milestones, 'Earnings Release' (ER) is the closest fit for a material, periodic-like update, although 'Regulatory Filings' (RNS) is a possibility if it were purely regulatory. However, the content is heavily focused on financial impact and operational progress, making ER more appropriate than the general RNS fallback, as it functions as an unscheduled earnings/guidance update. FY 2011
2011-06-30 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.